PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Albiglutide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Albiglutide is a once-weekly GLP-1 receptor agonist; in the Harmony Outcomes trial of 9,463 people with type 2 diabetes and cardiovascular disease, cardiovascular death, myocardial infarction or stroke occurred in 7% on albiglutide and 9% on placebo over a median 1.6 years (hazard ratio 0.78). · pmid:30291013

In the 32-week HARMONY 7 comparison, once-daily liraglutide lowered HbA1c more than once-weekly albiglutide (-0.99% against -0.78%); albiglutide caused more injection-site reactions and fewer gastrointestinal events. · pmid:24703047

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Albiglutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. (2014) · establishedAlbiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. (2018) · established20142018

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Albiglutide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. · pmid 24703047 · 2014
    • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. · pmid 30291013 · 2018
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.